Enhanced recovery after surgery (ERAS) protocols is extermely beneficial in liver surgeries – A metaanalysis.

Dr.Bhavin Vasavada.

Consultant Hepatobiliary and liver transplant surgeon,

Shalby hospitals,

Ahmedabad, India

Email:drbhavin.liversurgeon@gmail.com

Dr.Hardik Patel.

Consultant Hepatobiliary and liver transplant surgeon,

Shalby hospitals,

Ahmedabad, India

Keywords: Metaanalysis,ERAS, liver surgery,HPB surgery

Abbreviations: Enhanced Recovery After Surgery (ERAS), Weighted Mean Difference (WMD), Confidence Intervals.(C.I)

Conflict of interests:none

Financial disclosures:none

Contribution of authors:

Dr.bhavin vasavada was over all incharge of research and actively contrubuted in study design,data collection, conduction research,statistics, manuscript written, final approval. Dr.hardik patel helped in data collection, conduction research,statistics, manuscript writing.

ABSTRACT:

BACKGROUND: Enhanced recovery after surgery (ERAS) programs aim to improve postoperative outcomes.. This metaanalysis aims to evaluate the impact of ERAS programmes on outcomes following liver surgeries.

METHODS: EMBASE, MEDLINE, PubMed and the Cochrane Database were searched for studies comparing outcomes in patients undergoing liver surgery utilizing ERAS principles with those patients receiving conventional care. The primary outcome was occurrence of 30 day morbidity and mortality. Secondary outcomes included length of stay , functional recovery ,readmission rates,time to pass flatus,blood loss and hospital costs.

RESULTS: Ten articles were included in the metaanalysis. Overall 30 days mortality rates were 0.65% in ERAS group while 0.97% in standard group (p=0.997). 30 days morbidity rates were not different in ERAS group compared to conventional care patients. (20.2 % in ERAS vs. 25 % in non ERAS). (p=0.329).Hospital stay, time to pass flatus, time to complete recovery and hospital costs were also significantly reduced due to ERAS protocols. (p value <0.001 ,0.005,<0.001,and 0.038 respectively). There was no significant difference in blood loss and readmission rates between the two groups. (p=0.594, and 0.916 respectively)

CONCLUSIONS: The adoption of ERAS protocols significantly reduced morbidity, hospital stay, readmission rates, time to recovery, hospital costs, time to pass flatus. There were no significant differences in 30 day mortality and blood loss.

KEYWORDS: Enhanced recovery after surgery, liver surgery, HPB surgery, morbidity, mortality, liver resection, fast track surgery.

Introduction:

Early recovery after surgery (ERAS) protocol is beccoming gold standard in peri operative care with excellent reults in colorectal,gastiric and HPB surgeries. [1].
ERAS is a evidence based peri-operative protocol which has shown significnat improvements in perioperative outcomes.[2]. Desiptie these overwhelming evidences implementation of these protocols has been very slow and lack wide spread implementation.[3]

ERAS has initially developed for colorectal surgeries [4], However its impletation is being tested in all other field.[4] and it has now spread over other specialities.
ERAS protocols has been applied to liver surgeries also and found to be benefical.{5]

Primary Aim of this metaanalysis was to study the effect of ERAS protocols on 30 days morbidity and mortality. Secondary aim was to study effect of ERAS protocols

on hospital stay, readmission rates, time to recovery, time to pass flatus, and Hospital costs.

Material and Methods:

In this systemic review and metaanalysis we searched EMBASE, MEDLINE, PubMed and the Cochrane Database with key words like “liver surgery”,”Enhanced recovery after surgery”, “ERAS protocols”, “ERAS vs conventional liver surgery”, “ morbidity and mortality following liver surgery”, ‘liver resections”. Two independent authors extracted the data (B.V and H.P).

Systemic review and Metaanalysis was done according to MOOSE and PRISMA guidelines. (6,7).

Statistical analysis

The meta-analysis was conducted using Open metaanalysis software. Heterogeneity was measured using Q tests and I^2, and $p < 0.10$ was determined as significant (8). If there was no or low heterogeneity ($I^2 < 25$ %), then the fixed-effects model was used. Otherwise, the random-effects model was used. The risk ratio (RR) was calculated for dichotomous data, and weighted mean differences (WMD) were used for continuous variables. Both differences were presented with 95 % CI. For continuous variables, if data were presented with medians and ranges, then we calculated the means and SDs according to Hozo et al. (9). If the study presented the median and inter- quartile range, the median was treated as the mean, and the interquartile ranges were calculated using 1.35 SDs, as described in the Cochrane handbook.

Inclusion criteria:

Inclusion criteria:

1. Studies that compared ERAS protocols with that of conventional protocol
2. Minimum 25 numbers of patients
3. Means and standard devations or medians and range mentioned.
4. Full texts available
5. Prospective, retrospectives studies or randomised control trials included.
6. ERAS program should include most of the 17 items included according to ERAS group recommendation. [10].

Exclusion criteria:

1. Studies whose full texts can not be obtained.
2. Studies with no comparable groups [ERAS vs conventional]
3. Duplicate studies.

Assessment of Bias:

Characteristics of the studies are described in table 1. Identified studies were broadly grouped into 1 of 2 types, either randomized trials or cohort studies. Cohort studies were assessed for bias using the Newcastle-Ottawa Scale (10). Randomized trials were assessed based on the Cochrane Handbook. (11) (Table 2 and table 3)

Results:

Search results:

Total 190 studies identified from initial literature search, 157 studies were evaluated after duplicates removed. Only 57 studies included ERAS protocols, 34 studies full text obtained. 13 studies had comparable groups for conventional protocols. Out of it 10 studies included in final analysis as other studies did not include adequate ERAS protocols. [figure 1]. (13-22)

Total 1289 patients' outcomes were studied from these 10 studies. 618 in ERAS group and 618 in conventional group.

Metaanalysis:

Primary outcome measures:

30 days mortality:

3 patients died in ERAS out of 458 and 5 patient died in conventional approach out of 511.There was no significant difference between ERAS and conventional group. P=0.792.

30 days morbidity:

30 days morbidity rates were not difference between the two groups. P=0.329.114/593 patients developed complications in ERAS group vs 171/673 in conventional group.

Secondary outcomes:

We also evaluated hospital stay,time to functional recovery ,readmission rates, time to pass flatus, hospital coses and blood loss in ERAS protocols in liver surgery.

As shown in figure 3 hospital stay ($p<0.001$ WMD -2.191 and time to functional recovery ($p<0.001$, WMD -2.462) were significantly less in ERAS group however there was no differene in readmission rates.($p=0.916$)

There was no difference in blood loss between ERAS and conventional group. ($p=0.594$). (figure 4). Time to pass flatus and hospital costs were significantly lesser in ERAS group. ($p= 0.005$ and $p= 0.038$ respectively with WMD of -0.996 days and –1803.536 $ respectively).

Discussion:

Enhanced recovery after surgery though initially described for colorectal surgery is now becoming standard protocol for all surgeries and it has significantly reduced hospital stay and cost without affecting morbidity and mortality.[1-5]

Started from colorectal surgeries ERAS protocols has now moved to other branches of surgeries. Many authors have tried to study applications of ERAS protocols on liver surgeries. (13-22) and showed ERAS protocol has significant benefit over standard protocols however large number studies and quality metaanalysis are still missing. Purpose of this metaanalysis to compare outcomes between ERAS and conventional group.

After literature review we evaluated 10 studies in this metaanalysis 4 were Randomised cotrol trials (11-14) and 6 were prospective or retrospective cohort studies. (15-20).

We evaluated 30 days mortality and morbidity as primary outcomes and hospital stay,time to complete recovery (time to complete physical independence), readmission rates,time to pass flatus, blood loss and hospital costs as secondary out comes.

There was no difference in mortality and morbidity between the two groups.(figure 2). Hospital stay, time to functional recovery and time to pass flatus (4 studies) were also significantly different in both the groups. (WMD -2.191,Odds ratio 0.016, and WMD-2.462 respectively).

There was no difference between blood loss and readmission rates between the two group in the metaanalysis. Only 3 studies out of 10 evaluated hospital cost which was signiicantly lesser in ERAS group. (WMD -1803.536$).

There are some limitations of this metaanalysis as heterogeneity of studies was significantly random effect models were used. Except hospital stay at least one study did not evaluate other factors.

In conclusion ERAS programs in liver surgeries reduce hospital stay, readmission rates, time to recovery, time to pass flatus, hospital cost without affecting 30 days mortality and morbidity.

Refrences:

1. Pędziwiatr M, Mavrikis J, Witowski J, et al. Current status of enhanced recovery after surgery (ERAS) protocol in gastrointestinal surgery. Med Oncol. 2018 May 9;95.
2. Ljungqvist O, Scott M, Fearon KC. Enhanced Recovery After Surgery: A Review. JAMA Surg. 2017 Mar 1; 292-298.

3. Melnyk M , Casey RG, Black P, et al. Enhanced recovery after surgery (ERAS) protocols: Time to change practice? Can Urol Assoc J. 2011 Oct; 342-8
4. Ljungqvist O. ERAS--enhanced recovery after surgery: moving evidence-based perioperative care to practice. JPEN.Jul;38(5):559-66.
5. Bobby V. M. Dasari, Rasha Rahman, Shakeeb Khan et al. Safety and feasibility of an enhanced recovery pathway after a liver resection: prospective cohort study. HPB 2015, 700–706 .
6. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000 Apr 19;2008-12.
7. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009 Oct; e1-34.
8. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med. 1539–1558.
9. Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13.
10. Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. September 1, 2016.
11. HigginsJP, AltmanDG, GøtzschePC,et al. TheCochraneCollaboration'stool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

12. Lassen K, Soop M, Nygren J, et al. Consensus review of optimal perioperative care in colorectal surgery. Arch Surg :961–969
13. He F, Lin X, Xie F, et al.. The effect of enhanced recovery pro- gram for patients undergoing partial laparoscopic hepatectomy of liver cancer. Clin Transl Oncol. 2015
14. Jones C, Kelliher L, Dickinson M, et al Randomized clinical trial on enhanced recovery versus standard care following open liver resection. Br J Surg :1015–1024
15. Lu H, Fan Y, Zhang F, et al. Fast-track surgery improves postoperative outcomes after hepatectomy. Hepatogastroenterology 61:168–172
16. Ni CY, Yang Y, Chang YQ, et al.Fast-track surgery improves postoperative recovery in patients undergo- ing partial hepatectomy for primary liver cancer: a prospective rand- omized controlled trial. Eur J Surg Oncol 39:542–547.
17. sánchez-Pérez B, Aranda-Narváez JM, Suárez-Muñoz MA, et alFast-track program in laparoscopic liver surgery: theory or fact? World J Gastrointest Surg 2012;4;246–250.
18. R. M. van Dam, P. O. Hendry, M. M. E. Coolsen, et al. Initial experience with a multimodal enhanced recovery programme in patients undergoing liver resection. *British Journal of Surgery* 2008; 95: 969–975
19. Bobby V. M. Dasari, Rasha Rahman, et al. Safety and feasibility of an enhanced recovery pathway after a liver resection: prospective cohort study.

HPB 2015, 17, 700–706.

20. Jonathan B. Koea, Yatin Young, et al. Fast Track Liver Resection: The Effect of a Comprehensive Care Package and Analgesia with Single Dose Intrathecal Morphine with Gabapentin or Continuous Epidural Analgesia. HPB Surgery 2009. doi:10.1155/2009/271986.
21. Xiao Liang, Hanning Ying, MM, Hongwei Wang et al. Hongxia Xu, BN, Hong Yu, MD, Liuxin Cai, MD et al. Enhanced Recovery Program Versus Traditional Care in Laparoscopic Hepatectomy. Medicine;2016;95.
22. De-Xin Lin, Xuan Li ,Qi-Wen Yet al.Implementation of a Fast-Track Clinical Pathway Decreases Postoperative Length of Stay and Hospital Charges for Liver Resection. Cell Biochem Biophys 2011;61;413–419

Table 1 charecteristics of studies.

Study	Type of study	Number of patients in ERAS group	Number of patients in control group
bobbyv2015	COHORT	91	93
vandam2008	COHORT	61	100
koea2009	COHORT	50	50
lin2011	COHORT	56	61
jones2013	RCT	46	45
ni2013	RCT	80	80
sanchez2012	COHORT	26	17
HeF2015	RCT	48	38
lu2014	RCT	80	80
liang 2016	RCT	80	107

Table 2: Risk of bias summary of RCT. + denotes low risk of bias, – denotes high risk of bias.

	Random Sequence generation	Allocation Concealment	Performance Bias	Detection Bias	Attrition Bias	Reporting Bias	Other
jones2013	+	+	-	+	+	+	?
ni2013	+	+	-	-	+	+	+
HeF2015	+	+	-	+	+	+	+
lu2014	?	?	-	+	+	+	?
liang2016	?	?	-	-	+	+	-

Table 3 Assessment of bias in cohort studies. + Denotes low risk of bias, – denotes high risk of bias.

	Representative of exposed cohort	Selection of non exposed cohort	Ascertainment of Exposure	Demonstration that outcome was not present at start of study	Comparability of cohorts	Assess m-ent of outcomes	Adequate time for followup	Complete Follow up of cohort	Total score
bobbyv2015	+	+	+	+	+	-	+	+	7
vandam2008	+	+	+	+	-	-	+	+	6
koea2009	+	-	-	+	-	-	+	+	4
lin2011	+	+	+	+	+	-	+	+	7

sanchez2012	+	+	+	+	-	-	+	+	6



Figure 1. Search strategy according to PRISMA guidelines.



Metaanalysis of 30 days mortality. There was no significant difference between mortality between ERAS vs conventional approach.(p=0.999)



30 days Morbidity rates were significantly lesser in ERAS group p<0.001 odds ratio 0.329

Figure 2 metaanalysis of 30 days mortality and morbidity rates between ERAS vs conventional approach.



'orest plot for hospital stay. P < 0.001 weighted mean difference -2.191 (95% confidence interval 3.039- -1.343)



Readmission rates were same in both the groups. (p=0.916)



Times to functional recovery was also significantly lesser in ERAS group. P<0.001. weighted mean difference -2.462 (-3.826,-1.104)

Figure 3 metaanalysis of hospital stay, readmission rates and time to functional recovery.



Forest plot for blood loss. P=0.594.



Forest plot for time to pass flatus p=0.005. WMD= -0.996 (95% c.i -1.925- -0.068)



Forest plot for hospital cost p=0.038 WMD (-1803.536-- -569.964)

Figure 4. Metaanalysis for blood loss, time to pass flatus and hospital cost